Apricitabine

TargetMol
Product Code: TAR-T14313
Supplier: TargetMol
CodeSizePrice
TAR-T14313-1mg1mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14313-5mg5mg£145.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14313-1mL1 mL * 10 mM (in DMSO)£147.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14313-10mg10mg£178.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14313-25mg25mg£251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14313-50mg50mg£355.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14313-100mg100mg£540.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Apricitabine (SPD754; AVX754) shows promising antiretroviral efficacy, good tolerability and a low propensity for resistance selection in antiretroviral-naive HIV infection[2]. Apricitabine (SPD754; AVX754), the (-) enantiomer of 2?-deoxy-3?-oxa-4?-thiocytidine (dOTC), is a highly selective and orally active HIV-1 reverse transcriptase (RT) inhibitor (Ki=0.08 μM). It also inhibits DNA polymerases α, β, and γ with Ki value of 300 μM, 12 μM, and 112.25 μM, respectively[1].
CAS:
160707-69-7
Formula:
C8H11N3O3S
Molecular Weight:
229.25
Pathway:
Microbiology/Virology; Proteases/Proteasome
Purity:
0.98
SMILES:
Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1
Target:
HIV Protease

References

1. de Muys JM, et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.Antimicrob Agents Chemother. 1999 Aug;43(8):1835-44. 2. Cahn P, et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.AIDS.?2006 Jun 12;20(9):1261-8.